Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stramonium is a homeopathic drug prepared from the fresh plant Datura stramonium (Jimson weed), which belongs to the Solanaceae family[4][6][7]. In homeopathy, it is primarily used to manage symptoms of extreme mental and emotional disturbances, including intense fear, vivid hallucinations, convulsions, and various neurological disorders. Its key clinical indications include schizophrenia, mania, delirium, stammering, chorea, epilepsy, meningitis, headaches, and strabismus[1][2][4][8]. The core bioactive components are tropane alkaloids—atropine, hyoscyamine, and scopolamine—which antagonize muscarinic acetylcholine receptors (especially M2)[3][5][7]. These actions underpin its historical uses as a bronchodilator (antiasthmatic activity), anticholinergic agent, analgesic, and hallucinogen[3][7][12]. In non-homeopathic medical practice, stramonium has had limited and unsafe use for asthma, cough, and pain but carries significant risk of toxicity and is no longer recommended[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stramonium.